Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous HSCT followed by daratumumab in multiple myeloma
ChiCTR2100047227Phase 4Recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of daratumumab, lenalidomide and sargramostim in multiple myeloma (MM) (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Objective response rate. Started Jun 2021; status: recruiting.
02
Drugs
daratumumablenalidomidesargramostim
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2100047227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047227.